Dustin Wright
Dustin Wright is Vice President of Clinical Operations at IconOVir. He brings over 20 years of experience across all phases of drug development in pharmaceutical and biotechnology organizations. Prior to joining IconOVir, he was Senior Director, Clinical Operations Oncology at Gilead Sciences, where he built and oversaw multiple teams in support of Gilead’s oncology pipeline. Dustin […]
Julie Maltzman, M.D.
Dr. Julie Maltzman is a medical oncologist with broad experience built over 20 years across all phases of drug development. She joined IconOVir in Oct 2022 from a VP, Global Head of GI Cancers and Cancer Immunotherapy role at Roche/Genentech. There, Dr. Maltzman oversaw the successful registration and commercialization of Atezolizumab and Bevacizumab for HCC. […]
William Kaelin, M.D.
Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Kaelin was awarded the 2019 Nobel Prize for Physiology or Medicine, with co-recipients Sir Peter J. Ratcliffe and Dr. Gregg L. Semenza, for discoveries related to the […]
John Huynh, Ph.D.
John Huynh is the Chief Technology Officer at IconOVir Bio. He joins IconOVir from Ring Therapeutics, where he served as Senior Vice President of Technical Operations and was responsible for overseeing CMC development and manufacturing. Prior to joining Ring, he was a Vice President of Gene Therapy Technical Operations at PTC Therapeutics, where he helped […]
Nicole van de Leuv
Nicole van de Leuv is Head of Legal at IconOVir Bio. Nicole also serves as a Principal at Two River, where she provides legal and operational support to Two River and its portfolio companies. Prior to joining Two River, Nicole was Special Counsel at Cooley LLP, where she focused on mergers and acquisitions and other […]
Clodagh O’Shea, Ph.D.
Clodagh O’Shea is the Scientific Founder of IconOVir Bio and Chair of IconOVir’s Scientific Advisory Board. She is also the Wicklow Capital Chair and Professor of Molecular and Cell Biology at the Salk Institute, a Howard Hughes Medical Institute Faculty Scholar, Allen Distinguished Investigator, Adjunct Professor at UCSD and Director of the Redesigning Biology and […]
Owen Witte, M.D.
Owen received his undergraduate degree from Cornell and his M.D. from Stanford University. He completed postdoctoral research at MIT, then joined the faculty at UCLA where he was recently appointed as University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Owen is also a […]
William Kaelin, M.D.
Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Kaelin was awarded the 2019 Nobel Prize for Physiology or Medicine, with co-recipients Sir Peter J. Ratcliffe and Dr. Gregg L. Semenza, for discoveries related to the […]
Jakob Loven, Ph.D.
Jakob Loven, Ph.D., is a Managing Partner at Nextech Invest with over 20 years of experience in cancer research and translational medicine. An accomplished oncology-focused entrepreneur and life science venture capitalist, Jakob has extensive experience in creating, launching and building early stage therapeutic-focused biotechnology companies and was a co-founder of Relay Therapeutics (NASDAQ: RLAY) and […]
Helen Kim
Helen S. Kim is a Managing Director of Vida Ventures, a life sciences focused venture capital firm. Ms. Kim has over 28 years of experience in leadership roles in biotechnology. Most recently, Ms. Kim was a Partner at The Column Group. Prior, Ms. Kim served as Executive Vice President of Business Development at Kite Pharma, […]